AI NEWS Clipping
From Delays in Jecheon Hub Construction to Expanded Consulting in Gangneung, Natural Products and Green Bio Shift Focus from Building New Facilities to Commercialization Links and Verification Systems

Verifying usability rather than expanding infrastructure

The 30 billion won natural products standardization hub in Jecheon, promoted by North Chungcheong Province, has fallen behind schedule after GMP functions were added belatedly to strengthen facility competitiveness. Beyond a simple construction delay, the issue also exposed the need to first assess whether new equipment and facilities will actually be used in line with real demand, given that the existing Jecheon Oriental Medicine Natural Products Center is operating its equipment at only around 50 to 60 percent capacity.

This trend shows that the natural products industry is now moving beyond the stage of increasing buildings and equipment and into a phase where the reliability of raw material procurement and the credibility of performance recognition are being scrutinized. In the domestic herbal medicine supply-demand control system as well, controversy over verifying the record of purchasing 27 tons of domestically produced cnidium for 450 million won suggests that transparency in transactions and operations must be secured first in order to strengthen the industry’s foundation.


Expanding mechanisms that connect research outcomes to the market

The 2026 Green Bio C&A Partnering event held in Gangneung was operated with a structure in which research institutes, companies, and investors discussed technology commercialization and overseas expansion in one place. As the event marked its fifth year and expanded into a consultation-based program involving 18 institutions, it showed that regional bio policy is shifting away from being centered on research presentations and toward follow-up contracts and market access connections.

In the same context, the exhibition floor at the Gangneung conference presented examples of laboratory achievements being linked to raw material production, quality control, startups, and exports, including the localization of pharmaceutical ingredients based on medical cannabis components, a bracken-derived dementia treatment, and microalgae cosmetics. This suggests that competitiveness in the natural products industry is increasingly likely to be determined less by the number of individual papers and more by the ability to transfer technology, standardize manufacturing, and connect distribution channels.


AI eases bottlenecks in natural products development

The Rural Development Administration has built an agricultural and life sciences specialized large language model trained on academic papers and research reports, and plans to make it publicly available to everyone starting in January next year. The emergence of such a tool, which reduces the time researchers spend searching for and interpreting materials, can be seen as an attempt to resolve a bottleneck in which accumulated data had been difficult to turn into actual research productivity.

In the private sector as well, AI is becoming a means of speeding up the analysis of mechanisms of action in complex compounds and the screening of candidate substances. A case in which one company said it reduced the time needed for natural compound analysis and action prediction from more than 10 years to six months, along with the government’s review of ways to expand AI use and link it to projects and budgets, shows a trend toward addressing the long development timelines and low reproducibility that have been weaknesses of natural products research through both policy and technology.


Dual competition in overseas market access and proving functionality

At regional industry sites, there was also a clear movement to expand export opportunities by linking food, cosmetics, and medical tourism through overseas exhibitions and promotional briefings. The joint promotional exhibition held at the Shanghai Pudong New International Expo Center and the Medicity Daegu promotional briefing held in Osaka, Japan, showed that regional companies with limited growth potential in the domestic market alone are seeking breakthroughs by meeting overseas buyers and consumers directly.

However, overseas expansion and product diversification ultimately depend on how well functionality and trust can be proven. As seen in the recognition of red ginseng’s blood sugar regulation benefits and in pharmacopuncture research analyzing 1,912 medical records from 105 patients with hypertension, natural products and Korean medicine-based products and treatments are also being rapidly reorganized toward persuading consumers with data and indicators rather than anecdotal experience.